Omadacycline
Omadacycline is in phase III clinical trials for the treatment of complicated acute bacterial skin and skin structure infections (ABSSSI). It was granted qualified infectious disease product designation by FDA for the treatment of ABSSSI in 2013. And it received Fast Track designation for skin and soft tissue infection on November 06, 2015.
The compound was originally developed by Paratek, then licensed to Merck Sharp & Dohme in 2006.
General Information
Update Date：2016-01-27
- Drug Name：
- Omadacycline
- Research Code：
- BAY-73-7388; MK-2764; PTK-0796; PTK-796
- Trade Name：
- MOA：
- 30S ribosomal protein inhibitor
- Indication：
- Acute bacterial skin and skin structure infections (ABSSSI)
- Status：
- Phase III (Active)
- Company：
- Paratek (Originator) , Merck Sharp & Dohme
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-08-27
|
Molecular Weight | 556.65 | ||||||||||||
| Formula | C29H40N4O7 | |||||||||||||
| CAS No. | 389139-89-3 (Omadacycline); | |||||||||||||
| Chemical Name | 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- | |||||||||||||
| Omadacycline （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Synthesis & Impurities
Update Date：2016-04-14
